Brief Title
Serum Uric Acid Levels and Onset of Cardiovascular Diseases: a CALIBER Study
Official Title
Serum Uric Acid Levels and Initial Presentation of Cardiovascular Diseases: a CALIBER Study
Brief Summary
Serum uric acid level is a commonly measured biomarker. The association between serum uric acid level and the risk of developing cardiovascular diseases has been observed in some studies, while others showed controversial results. Estimation of this association may help to predict cardiovascular outcomes and may guide new treatment strategies. The hypothesis is that increased serum uric acid level is associated with a range of cardiovascular diseases.
Detailed Description
Smaller observational studies suggested that increased serum uric acid level is associated with increased incidence of several cardiovascular diseases. Associations with specific initial presentations of cardiovascular diseases have not been studied in large cohort from the general population, but may be of interest for use in risk prediction or to guide therapeutic strategies. The aim of this study is to estimate associations between serum uric acid level and initial presentation of a range of cardiovascular diseases. The study will use data from the CALIBER dataset of clinically collected electronic health record data from England. Patients enter the study when they have a blood urate measurement recorded in the dataset, and they are followed up until they experience one of the cardiovascular endpoints, death or transfer out of the participating primary care practice. This study is part of the CALIBER (Clinical disease research using linked bespoke studies and electronic records) programme funded from the National Institute for Health Research (NIHR) and Wellcome Trust. The central theme of the CALIBER research is linkage of the Inpatient Hospital Episode Statistics (HES) with primary care (Clinical Practice Research Datalink) and other resources. The overarching aim of CALIBER is to better understand the aetiology and prognosis of specific coronary phenotypes across a range of causal domains, particularly where electronic records provide a contribution beyond traditional studies. CALIBER has received both Ethics approval (ref 09/H0810/16) and ECC approval (ref ECC 2-06(b)/2009 CALIBER dataset).
Study Type
Observational
Primary Outcome
Initial presentation of cardiovascular diseases
Secondary Outcome
All cause mortality
Condition
Stable Angina
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
180000
Start Date
January 1998
Completion Date
February 2019
Primary Completion Date
February 2018
Eligibility Criteria
Inclusion Criteria: - Patients registered with a participating general practice during the study period - Age 30 years or older at study entry - No record of previous diagnosis of cardiovascular disease - Follow up for at least one year before the index date. Exclusion Criteria: - Patients without a measurement of blood urate level during the study period.
Gender
All
Ages
30 Years - N/A
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
, ,
Administrative Informations
NCT ID
NCT03425305
Organization ID
CALIBER 16-176R
Secondary IDs
RP-PG-0407-10314
Responsible Party
Sponsor
Study Sponsor
University College, London
Collaborators
Wellcome Trust
Study Sponsor
, ,
Verification Date
November 2017